Search results
Added:
3 weeks ago
Added:
10 months ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical…
View more
Added:
1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Added:
1 year ago
Added:
1 month ago
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the…
View more
Added:
1 month ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the…
View more
Added:
2 months ago
In this short interview, Dr Ellen Apperloo (University Medical Center Groningen, Groningen, NL) discusses the key outcomes of tirzepatide in a cohort of type 2 diabetes patients from a pooled post-hoc analysis of the SURPASS 1-5 clinical trials.Findings showed that tirzepatide was associated with reduced urine albumin-creatinine ratio (uACR) compared to all comparators, including semaglutide and…
View more
Added:
1 year ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were…
View more
Halim Yammine
Job title: Vascular Surgeon
Author
Added:
10 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
